Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure

Urban Alehagen, Ulf Dahlström, Jens F Rehfeld, Jens P Goetze

24 Citationer (Scopus)

Abstract

Use of new biomarkers in the handling of heart failure patients has been advocated in the literature, but most often in hospital-based populations. Therefore, we wanted to evaluate whether plasma measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-A-type natriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM), individually or combined, gives prognostic information regarding cardiovascular and all-cause mortality that could motivate use in elderly patients presenting with symptoms suggestive of heart failure in primary health care.
OriginalsprogEngelsk
TidsskriftJournal of Cardiac Failure
Vol/bind19
Udgave nummer1
Sider (fra-til)31-9
Antal sider9
ISSN1071-9164
DOI
StatusUdgivet - jan. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure'. Sammen danner de et unikt fingeraftryk.

Citationsformater